Investment Management Associates Inc. ADV Sells 78,852 Shares of Solventum Corporation $SOLV

Investment Management Associates Inc. ADV lessened its stake in shares of Solventum Corporation (NYSE:SOLV) by 30.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 180,097 shares of the company’s stock after selling 78,852 shares during the period. Solventum accounts for 3.9% of Investment Management Associates Inc. ADV’s holdings, making the stock its 12th largest position. Investment Management Associates Inc. ADV’s holdings in Solventum were worth $14,271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Crossmark Global Holdings Inc. lifted its position in shares of Solventum by 8.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 6,095 shares of the company’s stock worth $483,000 after buying an additional 500 shares during the period. Ethic Inc. lifted its position in shares of Solventum by 1.8% during the 4th quarter. Ethic Inc. now owns 9,390 shares of the company’s stock worth $744,000 after buying an additional 164 shares during the period. International Assets Investment Management LLC bought a new position in Solventum in the 4th quarter valued at $152,000. Sequoia Financial Advisors LLC raised its position in Solventum by 5.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 18,239 shares of the company’s stock valued at $1,445,000 after purchasing an additional 867 shares during the last quarter. Finally, BOKF NA raised its position in Solventum by 41.7% in the 4th quarter. BOKF NA now owns 3,108 shares of the company’s stock valued at $246,000 after purchasing an additional 915 shares during the last quarter.

Analyst Ratings Changes

SOLV has been the topic of several research analyst reports. Stifel Nicolaus decreased their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. BTIG Research reiterated a “buy” rating and set a $89.00 price target on shares of Solventum in a research report on Wednesday. Wells Fargo & Company decreased their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, Rothschild & Co Redburn began coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $85.91.

Insider Transactions at Solventum

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.24% of the company’s stock.

Solventum Stock Up 2.3%

NYSE SOLV opened at $73.30 on Friday. The stock has a fifty day moving average of $67.84 and a 200-day moving average of $74.50. The stock has a market capitalization of $12.69 billion, a P/E ratio of 8.98, a price-to-earnings-growth ratio of 1.10 and a beta of 0.59. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.89 and a current ratio of 1.07.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the firm earned $1.34 EPS. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts forecast that Solventum Corporation will post 6.59 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.